Thrombophilia. Dr. A Sarrafnejad PhD Dep. Immunology School of public health TUMS

Similar documents
Are there still any valid indications for thrombophilia screening in DVT?

Manifestation of Antiphospholipid Syndrome among Saudi patients :examining the applicability of sapporo Criteria

The Antiphospholipid Syndrome

Current View of the Treatment of Antiphospholipid Syndrome

Thrombophilia: To test or not to test

Thrombophilia. Diagnosis and Management. Kevin P. Hubbard, DO, FACOI

Approach to Thrombosis

DISCLOSURE. Presented by: Merav Sendowski, MD Oregon Health and Science University

Key words: antiphospholipid syndrome, trombosis, pathogenesis

Antiphospholipid Syndrome ( APS)

Thursday, February 26, :00 am. Regulation of Coagulation/Disseminated Intravascular Coagulation HEMOSTASIS/THROMBOSIS III

THROMBOSIS RISK FACTOR ASSESSMENT

Hemostasis. PHYSIOLOGICAL BLOOD CLOTTING IN RESPONSE TO INJURY OR LEAK no disclosures

COAGULATION INHIBITORS LABORATORY DIAGNOSIS OF PROTHROMBOTIC STATES REGULATION OF. ANTICOAGULANT PROTEIN DEFICIENCY Disease entities COAGULATION

Laboratory Evaluation of Venous Thrombosis Risk

Antiphospholipid antibodies

Antiphospholipid Syndrome

Mabel Labrada, MD Miami VA Medical Center

AN INTERESTING CASE OF RESPIRATORY DISTRESS. Dr.V.Akila Devi DNB PG Southern Railway Headquarters Hospital Chennai

Sindrome da anticorpi antifosfolipidi: clinica e terapia. Vittorio Pengo Clinical Cardiology, Padova, Italy

Thrombophilia. Stephan Moll, MD Medicine, Heme-Coag UNC Chapel Hill, NC. GASCO Atlanta Sept 8 th, Disclosures. Conflicts of interest: NONE

Antiphospholipid Syndrome Handbook

Updates in Diagnosis & Management of VTE

THROMBOPHILIA TESTING: PROS AND CONS SHANNON CARPENTER, MD MS CHILDREN S MERCY HOSPITAL KANSAS CITY, MO

Lupus Anticoagulants (LA), Antiphospholipid (APL) Antibodies & APL Syndrome: Review & Update. Antiphospholipid. Antiphospholipid

Pulmonary Thromboembolism

Consultative Coagulation How to Effectively Answer Common Questions About Hemostasis Testing Session #5000

Lupus as a risk factor for cardiovascular disease

Anti β 2. -Glycoprotein I and Antiphosphatidylserine Antibodies Are Predictors of Arterial Thrombosis in Patients With Antiphospholipid Syndrome

Potpourri of Hematology Oncology. Jasmine Nabi, M.D. Oncology Associates Hall-Perrine Cancer Center at Mercy

Genetic Tests for the Better Outcome of VTE? 서울대학교병원혈액종양내과윤성수

Mohammadreza Tabatabaei IBTO COAG LAB

VENOUS THROMBOEMBOLISM: DURATION OF TREATMENT

All about Antiphospholipid Syndrome. M.B. Agarwal, MD Prof & Head, Dept of Haematology, Bombay Hospital Institute of Medical Sciences, Mumbai, India

Antiphospholipid Antibody Syndrome: Management Issues for the Hematologist

PS + MPs PS - MPs 37% 36% 64% 64%

THROMBOPHILIA SCREENING

Sinus and Cerebral Vein Thrombosis

Diagnosis of hypercoagulability is by. Molecular markers

DOWNLOAD OR READ : POSITIVE OPTIONS FOR ANTIPHOSPHOLIPID SYNDROME APS SELF HELP AND TREATMENT PDF EBOOK EPUB MOBI

Inherited Thrombophilia Testing. George Rodgers, MD, PhD Kristi Smock MD

Thrombosis. By Dr. Sara Mohamed Abuelgasim

Patient with Musculo-skeletal Complaints - Summary

Anaesthesiologic management of a parturient with a known antiphospholipid syndrome

Review. The future of treatment for antiphospholipid syndrome. Rohan Willis* 1, Eon Nigel Harris 2 & Silvia Pierangeli 1

Antiphospholipid antibodies are a heterogeneous family

Anticardiolipin Antibodies in Patients With Type 2 Diabetes Mellitus

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

Pediatric thrombosis: Diagnosis and Management

Prevalence of antiphospholipid auto antibodies in patients with thrombosis

Hematologic Disorders. Assistant professor of anesthesia

ORIGINAL PAPERS. Marek Cieśla 1, B D, Ewa Wypasek 1, 2, B D 1, 2, A, E, F. Abstract

Faculty Disclosure. Hypercoagulable States. Learning Objectives. Hereditary Thombophilia. Acquired Hypercoagulable States 5/9/2016

Scott M. Stevens, MD. Co-Director, Thrombosis Clinic. Associate Professor of Clinical Medicine

Interactive Case Vignette: DOACs (Direct Oral Anti-Coagulants) vs. Warfarin for APLA (Anti-Phospholipid Antibody Syndrome)

Choosing Wisely: If, When, What, and Who to Test for Thrombophilia

Stanford University H IGH VALUE C ARE: OPTIMAL A PPROACH. Andre Kumar MD Tyler Johnson MD Neil Shah MD Jason Hom MD

APPENDIX 2 Eight New Cases of LAHS and Review of Literature: Treatment and Follow-Up

Case Report Lower Limb Ischemia: Aortoiliac Thrombosis Related to Antiphospholipid Syndrome (APS) Case Report and Review of the Literature

Daniel Egan, MD April 13, 2012

Epidemiologia e clinica del tromboembolismo venoso. Maria Ciccone Sezione di Ematologia e Fisiopatologia della Coagulazione

Dyslipidemia Endothelial dysfunction Free radicals Immunologic

Venous Thromboembolism Prophylaxis

Low-Molecular-Weight Heparin

ANTIPHOSPHOLIPID (HUGHES) SYNDROME

T he antiphospholipid syndrome (APS) is a thrombophilic

CLINICAL CASE PRESENTATION

What will we discuss today?

Venous thrombosis is common and often occurs spontaneously, but it also frequently accompanies medical and surgical conditions, both in the community

Chapter. Absolute risk of venous and arterial thrombosis in HIV-infected patients and effects of combination antiretroviral therapy

AMPLIADO SÍNDROME ANTIFOSFOLÍPIDO SÍNDROME DE SJÖGREN María José Cuadrado Lozano Clínica Universidad de Navarra-Madrid

Disclosures. Sneddon Syndrome: Untangling the Web. Case Presentation. MRI head w/ and w/o contrast. Further Workup. Further Workup 10/26/2017

Available Online at CODEN: IJRSFP (USA) Vol. 9, Issue, 3(L), pp , March, 2018.

Pulse 110/min beats per min + 20 Systolic blood pressure <100 mmhg Respiratory rate 30 breaths per min + 20

Antiphospholipid antibodies in patients with venous thrombosis at Kenyatta National Hospital

DVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients. David Liff MD Oklahoma Heart Institute Vascular Center

VENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK?

Summary of the 11th International Congress on Antiphospholipid Antibodies, Sydney, Australia, November 2004

APPENDIX 1 Eight New Cases of LAHS and Review of the Literature: Clinical and Laboratory Data

Menopausal Hormone Therapy & Haemostasis

Središnja medicinska knjižnica

Guidelines. 704 q 2000 Blackwell Science Ltd GUIDELINES ON THE INVESTIGATION AND MANAGEMENT OF THE ANTIPHOSPHOLIPID SYNDROME

Antiphospholipid antibody syndrome an overview

Review. Management of the antiphospholipid syndrome: new approaches

TECHNICAL SERIES. Lupus Anticoagulants: Basic Concepts and Laboratory Diagnosiss. ...Setting trends TULIP DIAGNOSTICS (P) LTD.

Venous Thromboembolism Prophylaxis - Why Should We Care? Harry Gibbs FRACP FCSANZ Vascular Physician The Alfred Hospital

Sciences, Tehran, Iran

Rituximab. B Cell Inhibition in APS. Methods. B Cell Inhibition in APS. Disclosure 11/6/2011

The Multi-Factorial Threshold Model of Thrombotic Risk

Original Policy Date

ESIM 2014 Clinical Case Presentation Israel. Ben-Sasson Maayan Bnei-Zion medical center Haifa

Updates in Medical Management of Pulmonary Embolism and Deep Vein Thrombosis. By: Justin Youtsey, Elliott Reiff, William Montgomery, Grant Finlan

Generate Knowledge Lupus Anticoagulant Testing Made Simple

DVT - initial management NSCCG

Challenges in Anticoagulation and Thromboembolism

L iter diagnostico di laboratorio nelle coagulopatie congenite emorragiche

Duration of Anticoagulant Therapy. Linda R. Kelly PharmD, PhC, CACP September 17, 2016

Lupus anticoagulant and anticardiolipin antibodies in SLE with secondary Antiphospholipid Antibody Syndrome

Heparin-Induced Thrombocytopenia. Steven Baroletti, PharmD., M.B.A., BCPS Brigham and Women s Hospital

Supplementary table to Bennett et al. Peripheral arterial disease and Virchow s triad (Thromb Haemost 2009; 101.6)

Transcription:

Autoimmune Thrombophilia Dr. A Sarrafnejad PhD Dep. Immunology School of public health TUMS Saraf@sina.tums.ac.ir

Acquired Thrombophilia HIT PNH Cyckle cell Anemia Myeloproliferative lf Diseases Thrombocytosis Cancers Nephrotic syndrome

HYPER HOMOCYSTEINEMIA Atherosclerosis

Acquired.Immune System IBD AIHA Autoimmune Thrombocytopenia MS SLE SJOGREN APS

The Consequences of Thrombosis in HIT are Often Severe Recovery 40-60% Permanent Disability (amputation, stroke) 20-30% Mortality 20-30% Van Cott EM. Heparin-induced thrombocytopenia. Turnaround Times 1996; 5:7-11

APLA syndrome was recognized as a distinct entity from the work of pioneers in the field Harris, Gharavi & hiscolleagues in 1983

APS morbidity APS is the most common cause of acquired thrombophilia. Prevalence in general population: 2-4% 15-20% of all DVT with or without PE. 1/3 of new strokes in patients < 50 years age. 10-15% women with recurrent pregnancy losses. APS: significant proportion of thromboembolic disease and pregnancy loss in SLE. APL Abs present in 30-40% SLE. One third of those patients have aeclinical camanifestations esaosof APS. acl positivity may precede a more severe form of SLE.

Antigens of antiphospholipid p p abs β2gpi Plasmin Prothrombin Protein C, S Platelet activating factor Annexin V Cardiolipin (CL) Oxidized CL Oxidized LDL, other PL. Tissue factor (TF)

Antigens of antiphospholipid abs Thrombomodulin Phospholipids Phospholipase A2 CD40/CD40L FVIII FX FXI FXII

APL antibodies and NF-κB Intracellular events in EC induced by apl antibodies: apl induce activation of NF-κB and correlates with EC activation in vitro and in vivo and with thrombosis in vivo. Espinola RG et al: J Thromb Haemost, 2003; 1: 843-848. Dunoyer-Geindre S. et al. Thromb Haemost. 2002; 88: 851-857. Bohgaki M, et al. Int Immunol. 2004; 16: 1632-1641.

Effects of AECA up-regulation of adhesion molecules, such as E-selectin, intercellular adhesion molecule (ICAM)-1, and vascular cell adhesion molecule-1 Owing to the concomitant production of chemokines by EC, this enhanced adhesion molecule expression facilitates the recruitement and the ensuing attachment of monocytes as well as polymorphonuclear neutrophils to the

Platelet and/or endothelial activation Role of cell-derived microparticles (MP) Role of complement

2004;13(9):649-52. Antiphospholipid antibodies as cause of pregnancy loss. During differentiation to syncytium, trophoblasts express cell membrane anionic phospholipids that can bind beta2 glycoprotein I, the main cationic phospholipid binding protein recognized by the antiphospholipid antibodies. Adhered beta2-glycoprotein I might be recognized dby the antibodies that, once bound, strongly interfere with in vitro trophoblast cell maturation so resulting in a defective placentation. These mechanisms have been suggested to play a role in early fetal loss, while thrombotic events would be responsible for miscarriages late in the pregnancy.

Predictive value of IgG acl for thrombosis in patients with SLE (Escalante et al) IgG acl levels below 21.4 = probability of thrombosis 0.07 IgG acl levels >21.4 and < 65.0 GPL = probability bilit of thrombosis 0.20 IgG acl levels >65.1 GPL units = probability of thrombosis 0.75

Anti-ß 2 2glycoprotein I More specific than anticardiolipin test for diagnosis of Antiphospholipid Syndrome (but not 100% specific) Not as sensitive as anticardiolipin test (70-90% sensitivity) Efforts of standardization continuing Useful in diagnosis of doubtful cases of APS. Some APS patients negative for acl and positive for antiβ 2 GPI.

Venous thrombosis, particularly of the lower limb, occurs in up to 55% of patients with the syndrome, half of whom also have pulmonary emboli. Arterial thrombosis involves the brain in up to 50% of cases, causing transient ischemic attacks or strokes. Other anatomic sites for arterial thrombosis are the heart (25%), causing coronary occlusion, and the eye, kidney and peripheral arteries (25%).

Causes By Mayo Clinic Infections : People with syphilis, HIV infection, hepatitis C and malaria, among others, have a higher incidence of having antiphospholipid antibodies.

Causes By Mayo Clinic Medications : Taking certain drugs, such as the high blood pressure medication hydralazine, the heart rhythm-regulating medication quinidine, the anti-seizure medication phenytoin (Dilantin) and the antibiotic amoxicillin may lead to an increased risk

Causes By Mayo Clinic Genetic predispositions: Although the disorder isn't considered hereditary, research indicates that relatives of people with antiphospholipid syndrome are more likely to have the antibodies

COMMONLY ENCOUNTERED ACQUIRED RISK FACTORS Heparin-Induced Thrombocytopenia (HIT) Surgery Immobilization Malignancy Pregnancy Oral Contraceptives Estrogen Replacement Therapy Lupus Anticoagulant Anticardiolipin & Anti-Beta 2 Glycoprotein 1 Antibody Obesity Smoking

Most People Have More Than 1 Risk Factor for Thrombosis THROMBOSIS Plane Ride RISK THROM MBOSIS NO THROMBOSIS Factor V Leiden OCP Factor V Leiden Injury to Leg OCP Factor V Leiden ANT TICOAGULANT T PR ROPHYLAXIS Injury to Leg OCP Factor V Leiden At Birth At 25 yo At 38 yo At 43 yo